CommercialAdministrativeMedium impact
08.02.33a, Guselkumab (Tremfya®) Injection for Intravenous Use
Independence Blue Cross·Dermatology, Rheumatology·Pharmacy
Effective date
Apr 1, 2026
We identified it
Jun 19, 2026
Summary
This is a policy reissue for Guselkumab (Tremfya®) injection for intravenous use under commercial plans. The policy has been reposted with an effective date of April 1, 2026, likely containing updated coverage criteria or administrative requirements for this specialty biologic medication used primarily in dermatology and rheumatology.
Action Required
Before April 1, 2026: Billing team should review the full policy text at the provided URL to identify any changes to prior authorization requirements, coverage criteria, or billing guidelines for Guselkumab (Tremfya®) IV injections. Update billing protocols and staff training materials accordingly for commercial plan submissions.